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Background: Generous endograft oversizing has been associated with propensity for aortic neck dilation and subsequent
device migration in endografts without suprarenal fixation. Effects of variable oversizing of endografts with suprarenal
fixation have been poorly studied.
Methods: Three hundred fifty-one patients underwent endovascular AAA repair (EVAR) in a prospective multicenter trial
using the Zenith AAA Endovascular Graft, a fully supported bifurcated 3-piece endograft with barb-enhanced suprarenal
stent fixation. Blinded core-laboratory measurement of variables was prospectively recorded at predischarge and at 1, 6,
12, and 24 months after the procedure. Potential influence of endograft oversizing on subsequent aortic neck dilation
(minor axis), aneurysm shrinkage (major axis), device migration, endoleak, rupture, open conversion, and death were
retrospectively studied. Data are given as mean  SEM.
Results: Risk of endograft migration (>5mm) at 12 months was 2.3% (6/261). However, patients with endograft
oversizing of >30% had a 14% (4/29) migration risk compared with those oversized <30% (0.9%, 2/232), P < .002.
There was zero device migration by the SVS definition (>10 mm or clinical event). Device oversizing >30% was associated
with decreased AAA sac shrinkage (48% vs 77%) and with increased sac enlargement (9.5% vs 0.6%) at 24 months when
compared with oversizing of<30%, respectively (P .001). Incidence rate of any endoleak at 12 and 24 months was 8.2%
(21/256) and 7.1% (12/169), respectively. Oversizing of endografts by >30% was associated with an increased type II
endoleak rate (11 vs 4.7%) that failed to reach statistical significance (P  .27). Aortic neck diameters increased
significantly by 6 months (P < .001) but then stabilized through 24 months; the absolute changes at 1 (n  298), 6
(n  278), 12 (n 264), and 24 months (n 171) were 0.66  0.10 mm (3.0%), 1.32  0.11 mm (5.6%), 1.38  0.12
mm (5.9%), and 1.44  0.16 mm (6.1%), respectively. Linear regression analysis demonstrated no correlation between
endograft oversizing and aortic neck dilation at 12 (P  .86) or 24 months (P  .64).
Conclusions: Device migration and endoleaks were very infrequent after treatment with the Zenith AAA Endovascular
Graft. However, endograft oversizing of >30% was associated with an14-fold increase in device migration (>5 mm) at
12 months and with a 16-fold increased risk of AAA expansion at 24 months. Although further follow-up will be
essential to assess whether these early associations continue, avoidance of excessive endograft oversizing is recommended.
(J Vasc Surg 2004;39:20-6.)
Precise sizing of aortic endografts increasingly has been
recognized as an important element in attaining optimal
early and late outcomes after endovascular abdominal aor-
tic aneurysm repair (EVAR). In particular, the increased
risk of type I endoleaks with inadequate oversizing has been
emphasized. Mohan et al1 found that the risk of type I
endoleaks was significantly increased with oversizing of
10%. Using a model derived from these clinical data, they
predicted a reduced type I endoleak rate with 10% to 20%
device oversizing.1
Most endograft manufacturers indeed recommend a de-
vice oversize of 10% to 20% greater than the minor axis of the
aortic neck. This degree of oversizing generally translates into
use of an endograft that is 3 to 5 mm larger than the adventi-
tia-to-adventitia measurement of the minor-axis aortic neck
diameter. However, greater amounts of oversizing have been
selectively used for a variety of reasons, including the percep-
tion that larger oversizing might be beneficial for treatment of
challenging aortic neck anatomy.2 However, Conners et al3
found an association of 20% device oversizing with late
aortic neck dilation and subsequent endograft migration. In
that study, a self-expanding, modular, fully nitinol-supported
device without hook or barb fixation had been employed.3 It
is unknown whether other endograft designs will react simi-
larly to generous oversizing.
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The purpose of this study was to examine the potential
influence of device oversizing on subsequent endograft
migration, aneurysm sac changes, endoleak, and aortic neck
dilation using a fully supported trimodular device with
suprarenal barb-enhanced fixation.
METHODS
This study was a retrospective analysis of multicenter
data that was prospectively collected by a core-laboratory
facility. Patients for EVAR were enrolled in the Zenith
multicenter clinical trial. (For a list of the Zenith investiga-
tors, see the Appendix.) There were 3 EVAR cohorts:
standard–medical risk group, high–medical risk group, and
a “roll-in” group, consisting of patients with either stan-
dard or high medical risk. All groups had to conform to
similar anatomic inclusion criteria and were thus pooled for
purposes of this study. Detailed inclusion and exclusion
criteria have been detailed elsewhere.4 Briefly, anatomic
inclusion in the trial required an aortic neck of 15 mm in
length and 28 mm in diameter, with 10% change in
diameter in the first 15 mm of the neck. Angulation of the
aortic neck to the aneurysm sac or the suprarenal aorta was
limited to 60° and 45°, respectively.
The Zenith AAA Endovascular Graft is a bifurcated
3-piece device. It has a bare suprarenal stent with 10 to 12
barbs for enhanced fixation. It is fully supported with
self-expanding Z-stents, placed on the inside of the Dacron
material at the aortic and iliac fixation sites, and on the
exterior of the device in the remainder of the body and
limbs. The 5 available body lengths are designed to place
the bifurcation of the device close to the iliac artery bifur-
cation. Aortic component devices are available in sizes from
22 to 32 mm, delivered through preloaded 18- to 20-Fr.
sheaths. Iliac diameters extend to 24 mm, allowing treat-
ment of ectatic common iliac vessels.
Anatomic patient selection was rigorously controlled
by physician film reviewers who had no clinical interaction
with the patient. Candidates were rejected from inclusion
in the study if they did not fall within the previously
described anatomic criteria. The suggested device oversiz-
ing at the aortic neck was 10% to 15%. The graft size that
was implanted was based upon the collaboration between
the national study proctors and investigator at each site.
However, the site investigator made the final determination
of all device sizing, including aortic oversizing.
Patients underwent computed tomography (CT) scan-
ning postoperatively (within 7 days), then at 1, 6, and 12
months, and yearly thereafter. The study protocol man-
dated a CT slice thickness of3 mm. CTs with and without
intravenous contrast were required. Anatomic measure-
ments used in this study were made by the study core
laboratory personnel. Potential variation in measurement
between investigative sites and the core laboratory was not
examined.
Axial CT images were assessed on computer worksta-
tions (NIH Image), and measurements were performed
electronically. A physician reviewer evaluated all chosen
table positions against the entire CT as well as the outline of
the vessel. Thus, all measurements were reviewed by a
minimum of two people. Formal measurement of interob-
server and intraobserver variability was not performed.
Other imaging modalities (arteriograms, CT arteriograms,
magnetic resonance arteriograms, and 3-D CT reconstruc-
tions) were not routinely required. Aortic neck diameter
was measured in its minor axis from adventitia to adventitia.
This measurement was taken at the ostium of the lowest
renal artery. AAA sac size was measured at its major axis.
The initial postoperative CT measurement of AAA size was
employed as the baseline for subsequent comparison for
changes is AAA sac size. Potential migration of the en-
dograft was assessed by measuring the distance between the
top of the bare suprarenal stent and the lowest renal artery.
In cases in which the ostium of the lowest renal artery was
seen in more than 1 cut, the image representing the more
caudal aspect of the vessel was employed. The junction of
the uncovered suprarenal stent and the covered portion of
the endograft could not be reliably seen on axial CTs.
Therefore, direct measurement of the distance between the
lowest renal artery and the covered portion of the device
was not possible.
Continuous and dichotomous measures were assessed
using independent 2-sample t tests and Yates-corrected
Pearson 2 tests, respectively. Change with time was as-
sessed with multivariate repeated-measures ANOVA. Mul-
tivariate logistic regression was performed to assess predi-
cate factors of outcome. All analyses were performed using
Systat version 10.2 (SPSS, Chicago, IL). A P value of.05
was considered significant.
The study design of this trial was a collaborative effort
of the national primary investigators (R.K.G. and
T.A.M.C.) and Cook, Inc, the study sponsor. Cook was
also involved with data collection. The primary author
(W.C.S.) and coauthors had unfettered access to all raw and
tabulated data, including the source-imaging studies. Thus,
the authors of this paper are solely responsible for the data
analysis and interpretation, manuscript preparation, and
timing of the manuscript’s oral presentation and ultimate
publication.
RESULTS
Three hundred fifty-one patients were treated with the
Zenith AAA Endovascular Graft in a multicenter FDA
phase II trial. These patients included all standard-risk,
high medical–risk, and “roll-in” cohorts. Of these, the large
majority (88%, 309) had endograft oversizing of 30%,
whereas 12% (41) had endografts that were oversized by
30%. There were 1 or more patients in whom the en-
dograft was oversized by 30% at 13 of 15 investigative
sites (range, 0 to 7 patients). One patient received a custom
device and was excluded from these analyses.
Migration. By recently revised Society for Vascular
Surgery reporting standards, migration is considered to be
10-mm movement of the device or any endograft dis-
placement with associated need for a secondary procedure.5
By this definition, endograft migration was zero (0/261) at
12 months. However, more modest caudal migration (5
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 1 Sternbergh et al 21
mm) was noted in 2.3 % (6/261) of patients at 12 months.
No cranial migration was observed. Endograft oversizing of
30% was associated with a14-fold increase in the risk of
device migration (5 mm) at this time point: 14% (4/29)
incidence vs 0.9% (2/232) with 30% oversizing (P 
.002). No patient with migration had clinical sequelae or
need for a secondary procedure. A single barb fracture was
seen in 1 patient with migration. Possible associated ana-
tomic risk factors for migration were also examined (Table
I). At 12 months, endograft oversizing was the only pre-
dictor of device migration ( 5 mm) with univariate and
multivariate analysis. There were no significant differences
in aortic neck length, diameter, angulation, or shape in
patients with or without migration.
Additionally, the association of a flared aortic neck with
device oversizing was examined. Patients with flared aortic
necks were defined as those with 3 mm aortic neck
enlargement that measured 15 mm caudal to the lowest
renal artery ostium. There was a 15% (45/305) and 27%
(11/41) rate of flared aortic necks in patients with 30%
and 30% device oversizing, respectively (P  .08). There
was no significant relationship between a flared neck and
neck dilation at 12 months (P .09) or at 24 months (P
.40) by linear regression analysis.
AAA shrinkage. At 12 months, the entire cohort (Fig
1), 65% (174/268) experienced significant shrinkage (5
mm sac reduction), 34 % (91/268) remained unchanged
(5 to  5 mm), and 1.1 % (3/268) enlarged (5 mm).4
At 24 months (Fig 2), there was a 73% (128/175), 25%
(44/175), and 1.7% (3/175) rate of shrinkage, stability,
and growth, respectively. Endograft oversizing by 30%
was associated with a lower shrink rate (48% vs 77%) and
with a16-fold higher expansion rate (9.5% vs 0.6%) at 24
months that was significant (P  .001; Fig 2).
Aortic neck dilation. When compared with the pre-
operative measurements, there was no significant increase
in neck diameter at the immediate postimplant measure-
ment (0.07  0.12 mm, P  .57). When compared with
the immediate postimplant diameter, there was significant
aortic neck dilation by 6 months (1.3 mm, P  .001) that
Table I. Possible anatomic risk factors for endograft migration (5 mm) at 12 months
Risk factor No migration
Migration
(5 mm)
Odds ratio
(95% confidence limits) P value (statistic)
Neck diameter, mean  SEM (n) 24.5  0.2 (253) 24.3  0.6 (6) 0.972 (0.72, 1.31) .85 (t test)
Neck length, mean  SEM (n) 33.3  1.0 (254) 24.6  7.0 (6) 0.952 (0.89, 1.02) .17 (t test)
Neck angulation, mean  SEM (n) 21.2  1.1 (210) 27.3  6.1 (4) 1.023 (0.97, 1.08) .44 (t test)
Neck shape, % (n) .67 (Fisher’s exact test)
Funnel 0.8 (2/255) 0 (0/6) NA
Inverted funnel 6.7 (17/255) 0 (0/6) NA
Irregular§ 9.4 (24/255) 17 (1/6) 1.77 (0.20, 15.76)*
Parallel 83 (212/255) 83 (5/6)
Endograft oversizing, % (n) .0016† (Fisher exact test)
30% 99 (230/232) 0.9 (2/232)
30% 86 (25/29) 14 (4/29) 18.4 (3.22, 106.01)‡
NA, Not applicable.
*Odds ratio comparing irregular with parallel.
†Multivariate analysis confirmed endograft oversizing as the sole predictor for device migration at 12 months.
‡Odds ratio comparing 30% to 30%.
§Asymmetric bulge.
Fig 1. Effect of device oversizing (30% vs 30%) on AAA sac behavior at 12 months. AAA shrinkage (Shrink) was
considered 5 mm reduction, Unchanged was 5 to 5 mm change, and Growth was 5 mm increase in size.
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then plateaued through 24 months (Table 2 ). Percentage
of device oversizing did not correlate with aortic neck
dilation at 12 months (r2  0; P  .86) or 24 months
(r20.001; P  .69) by linear regression.
Endoleak. Risk of any endoleak was 8.2 % (21/256)
at 12 months and 7.1 % (12/169) at 24 months. Most of
these endoleaks were type II. Risk of a type I or III
endoleak was 1.9% (5/256) at 12 months and 0 (0/169) at
24 months.4 Potential effect of device oversizing is shown
in Table III. There was a 50% higher incidence rate of
type II endoleaks with 30% device oversizing (4.8% vs
11%) that did not achieve statistical significance at 12 (P 
.17) or 24 months (P  .27).
Nine patients were identified intraoperatively with a
proximal Type I endoleak, as noted by the site. Per proto-
col, aggressive treatment of Type I (proximal or distal) and
Type III endoleaks was required. Treatment for the proxi-
mal Type I endoleaks identified during the procedure was
physician dependent and ranged from use of a molding
balloon (5 patients), molding balloon and Zenith main
body extension (1 patient), and Zenith main body exten-
sion and commercially available stent (1 patient). Addition-
ally, 1 patient was not treated at the time of the procedure,
and this patient’s Type I endoleak resolved by the time of
hospital discharge. One additional patient had an endoleak
that remained at the time of hospital discharge.
Other end points. There was 1 late rupture in the
entire cohort, occurring in the group whose endografts
were oversized by 30% (0.3% [1/309] vs 0 [0/41], P 
.99). Late open conversions were also infrequent and not
statistically different between groups (1.3% [4/309] vs
2.4% [1/41], P .99). There were no conversions to open
repair in the first 30 days after EVAR. Finally, death at 12
months (6.1% [19/309] vs 7.3% [3/41], P  .99) and 24
months (12% [38/309] vs 20% [8/41], P  .30) was not
different between those oversized 30% or 30%,
respectively.
DISCUSSION
Potential influence of endograft oversizing on subse-
quent adverse events after EVAR was evaluated from pro-
spectively collected multicenter data.
Oversizing and migration. Using this robust and
impartial database, device migration at 12 months was
found to be infrequent after treatment with the Zenith
AAA Endovascular Graft. By the SVS definition of migra-
tion, there was zero incidence of endograft migration at 12
Fig 2. Effect of device oversizing (30% vs 30%) on AAA sac behavior at 24 months. AAA shrinkage (Shrink) was
considered 5 mm reduction, Unchanged was 5 to 5 mm change, and Growth was 5 mm increase in size.
Table II. Changes in aortic neck diameter
Parameter
Follow-up (mo)
1 6 12 24
n 298 278 264 171
% Change
(mean  SEM)
3.0  0.4 5.6  0.4 5.9  0.5 6.1  0.7
Absolute change
(mm)
0.7  0.1 1.3  0.1 1.4  0.1 1.4  0.2
Table III. Possible effect of endograft oversizing on
endoleak
Endoleak type
Follow-up
(mo)
Endograft oversizing, % (n)
P30% 30%
All 12 7.9 (18/229) 11 (3/27) .47
Type I & III 12 2.2 (5/229) 0 (0/27) .99
Type II 12 4.8 (11/29) 11 (3/27) .17
Type IV 12 0 0 NA
All 24 6.7 (10/150) 11 (2/19) .63
Type I and III 24 0 0 NA
Type II 24 4.7 (7/150) 11 (2/19) .27
Type IV 24 0 0 NA
NA, Not applicable.
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months. By a stricter definition of migration (5 mm),
2.3% were noted to have caudal movement of the device at
12 months. Of these, 30% device oversizing was associ-
ated with a 0.9% (2/232) rate of migration, whereas there
was a 14.1% (4/27) rate of migration in patients with
30% oversizing. These differences were highly significant
(P  .001). Univariate and multivariate analysis of ana-
tomic aortic neck characteristics failed to demonstrate any
other significant variables that were associated with device
migration.
Migration of the Zenith endograft has been an uncom-
mon event in previous reports. In a single-center series
from the University of California at San Francisco, no
episodes of migration were seen after treatment of 116
patients with the Zenith endograft with a mean follow-up
of 10.3  9.8 months (range, 1 to 34 months).6 The
Nottingham group reported a 5-year experience (mean
follow-up of 20.6  14.9 months) with the Zenith en-
dograft, with only a single episode of migration (1/94,
1.1%).7 This case was associated with late aortic neck dila-
tion. The 5-year cumulative migration rate in this study was
7% by Kaplan-Meier analysis.7 Finally, Greenberg et al8
reported on 528 patients treated in Europe, Australia, and
the United States with a mean follow-up of 14 months
(range, 1 to 36 months). In this large data set, 8 patients
who had been treated with an earlier prototype of the
device with fewer suprarenal barbs had migration at 2 to 3
years after implantation.8
Experimental studies have suggested that the suprare-
nal barb fixation of the Zenith endograft resists migration
more rigorously than does many other endograft designs.9
The mean displacement force in a cadaveric model for the
Zenith device was 24 N. An endograft with infrarenal
hooks required 12.5 N, whereas a third endograft relying
on radial force required only 4.5 N of displacement force.9
Aortic necks with larger diameters and significant angula-
tion create greater static downward forces on the en-
dograft, exceeding 8 to 12 N in some anatomic cases.10
This dynamic flow modeling has been confirmed in the
clinical observation of high migration rates in patients with
large aortic necks after treatment with an endograft without
active fixation.11
The etiology of increased migration (5 mm) with
30% device oversizing is unclear. The multiple suprarenal
barbs of the device are frequently transmural in the aorta,
with forceful caudal movement causing aortic tears in ex-
perimental models.9 This scenario is unlikely, as no supra-
renal pseudoaneurysms have been seen in these patients.
Migration of the device could infer failure of the barbs.
However, isolated single-barb fractures have been seen in
only a few patients. Moreover, the number of barbs (10-12)
on the Zenith device was designed to provide redundant
protection from migration. A second possible failure mode
of the barbs would be initial failure of the barbs to penetrate
the aorta. Routine use of a compliant “molding” balloon
during implantation encourages engagement of the barbs.
The downward orientation of the barbs may require 2 to 3
mm of device migration for full engagement of the aorta.
Experimental models with Gianturco Z stent-based en-
dografts have demonstrated folds in the proximal fabric
with stent oversizing.12 These folds or invaginations in the
fabric grew larger with increases in stent oversizing. Al-
though type I endoleaks would seem to be the greatest
concern regarding such a phenomenon, theoretically fixa-
tion of the device could also be compromised.
Oversizing and aortic neck change. Changes in aor-
tic neck diameter after EVAR could have important impli-
cations in long-term durability of this treatment. Significant
dilation may lead to loss of seal or to fixation of the
endograft, causing a proximal type I endoleak, caudal en-
dograft migration, or both. The mechanisms of attaining a
proximal seal and secure fixation differ significantly among
endograft designs. The propensity for these severe adverse
events after late aortic neck dilation could be device depen-
dent, although this is speculative. Finally, the amount of
late aortic neck dilation itself may be endograft dependent.
The present study found a small but significant change
in aortic neck diameter at 6 months after implantation that
then stabilized at 12 and 24 months. What factors might
predispose to late aortic neck dilation? Conners et al3 found
a strong correlation with 20% device oversizing and sub-
sequent late neck dilation at 2 and 3 years after treatment
with a self-expanding, modular, fully nitinol-supported de-
vice. However, increased device oversizing did not appear
to accelerate aortic neck dilation by the 2-year mark in the
present study. The reasons for disparity of these observa-
tions are speculative. The most obvious explanation is that
different endograft designs may have variable late effects on
the aortic neck. However, other anatomic factors or differ-
ences in other patient characteristics cannot be excluded as
contributing factors.
Oversizing and endoleak and shrinkage rates. De-
vice oversizing by30% had a negative impact on AAA sac
behavior. At 24 months, the risk of AAA growth was
elevated by 16-fold (9.5% vs 0.6%), and the incidence of
AAA shrinkage was decreased (48% vs 77%) in those with
30% and30% oversizing, respectively. In previous stud-
ies with Zenith13 and other endograft devices,14 increased
endoleak rates have been associated with a decrease in AAA
shrinkage.
In the current study, endoleaks were infrequent after
treatment with the Zenith device (8.2% and 7.1% at 12 and
24 months, respectively). This low endoleak rate compared
favorably with that seen with other endografts. Endoleak
rates at 12 and 24 months in AneuRx trial patients15 were
13.9% and 16.7%, and in Excluder trial patients,16 the rates
were 17% and 20%, respectively. In the Zenith study,30%
device oversizing was associated with50% increase in type
II endoleaks that did not achieve statistical significance.
There were no differences in the more troublesome type I
endoleak, but it is possible that some of the increase in type
II endoleaks may have actually been misclassified type I
leaks. Thus, although it would appear intuitive that higher
endoleak rates might negatively affect shrink rates, a robust
statistical correlation is lacking. As such, the underlying
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explanations for the striking negative effect of 30% device
oversizing on AAA sac behavior remain speculative.
Could the choice of 30% device oversizing simply be
a marker for adverse anatomic characteristics that are
known to negatively affect outcome? This study demon-
strated no statistically significant differences in this area but
did find some trends that ultimately could be clinically
important. Those patients who experienced migration (5
mm) at 12 months had shorter aortic necks (24.6 vs 33.3
mm, P  .17). Although this was not statistically signifi-
cant, it is well known that the risk of migration increases
with progressively shorter necks. There were a modestly
greater percentage of patients with flared aortic necks in
patients who had30% device oversizing (27% vs 15%, P
.08). Patients with a flared aortic neck likely have a greater
likelihood of late aortic neck dilation and resultant delete-
rious effects such as type I endoleaks or migration. Al-
though this trend was not significant, further follow-up of
possible such adverse anatomic findings is warranted.
Limitations. Conventional measurement of en-
dograft migration could not be performed with this en-
dograft. Direct measurement of the distance between the
lowest renal artery and the endograft was not possible
because CT could not reliably appreciate the end of the
bare suprarenal stent and the beginning of the endograft.
Thus, a surrogate measurement from the top of the supra-
renal stent to the lowest renal artery was employed. This
longer length may have increased the chance for relative
inaccuracies in measurement of migration. However, the
absence of any observed cranial migration would suggest
that the measurement of caudal migration was not a ran-
dom measurement error.
CONCLUSIONS
Device migration and endoleaks were very infrequent
after treatment with the Zenith AAA Endovascular Graft.
However, oversizing of 30% was associated with an in-
creased rate of device migration at 12 months and with a
negative effect on late AAA sac changes. Endoleak occur-
rence and late aortic neck dilation were not significantly
changed by oversizing. The underlying etiology for in-
creased caudal movement (of5 mm) and AAA sac growth
with generous oversizing is speculative. Although further
follow-up will be essential to assess whether these early
associations continue, avoidance of excessive endograft
oversizing is recommended.
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DISCUSSION
Dr Wesley S. Moore (Los Angeles, Calif). This was an
excellent presentation and superbly analyzed; however, I’m still
not totally convinced that the adverse effect of migration is related
to the oversizing of the prosthesis. It is more likely related to the
reasons that oversizing was selected to begin with.
You mentioned two possible reasons, including short neck or
extreme angulation; perhaps there are more. These reasons for
oversizing reflect the adverse effect based on patient selection
rather than the generic consequence of oversizing per se. Clearly,
there is no reason that one would want to excessively oversize
unless you were trying to compensate for some particular adverse
anatomic problem. Clearly there was a trend toward shorter necks
in your series. Even though this trend wasn’t statistically significant
in your analysis, that may be a sample size problem and a type II
error. Would you like to comment?
Dr Charles Sternbergh III. Thank you for those comments,
and I couldn’t agree more. We looked very hard for anatomic
characteristics that might explain the correlation between 30%
device oversizing and adverse events. As shown in this presenta-
tion, we could not identify any statistically significant associations;
aortic neck length did trend shorter, although the differences were
not statistically significant. The rate of endoleak was half of that in
the patients who were oversized less than 30% than in the patients
who were oversized greater than 30%, but this too was not statis-
tically significant. Increased endoleak rates have correlated with a
decrease in the chance of aneurysm shrinkage; but again, those
trends were not significant.
Dr Jacob Buth (Eindhoven, The Netherlands). I also would
like to congratulate Dr Sternbergh for an excellent paper. My
question is this: How did you get to the threshold of 30%? Was this
handpicked or was there any graphical or mathematical method
used, like a ROC curve?
Dr Sternbergh. That’s an excellent question. No, there were
not ROC curves developed for this study. Thirty percent was
chosen because it was double the size of the recommended maxi-
mum oversizing, which was 10% to 15%.
Dr David C. Brewster (Boston, Mass). Dr. Sternbergh, I’m a
little surprised about migration with suprarenal hooks. I can un-
derstand where oversizing of a device without such fixation might
be associated with a higher incidence of migration, but wouldn’t
one expect that suprarenal hook fixation would prevent that? And
secondly, as a participant in the Zenith trial, the device selection
was pretty tightly controlled, as I remember, by the sponsor, so
why would 30% oversizing occur in certain patients if that wasn’t
desirable?
Dr Sternbergh. I’ll start with your first question. I agree that
any incidence of migration, frankly, was somewhat surprising based
on the suprarenal barb fixation. But the data do suggest a small
chance of migration (25 mm) despite the suprarenal fixation.
In regard to the choice of oversizing, I, too, was surprised to
find that a number of the patients had this excessive oversizing.
And while I too recall that there was some significant oversight in
terms of sizing of these devices, it was ultimately left to the
discretion of the investigator.
Dr Piergiorgio Cao (Perugia, Italy). You report low inci-
dence of migration, which is quite different from our experience.
We had a higher incidence of migration with a different kind of
endograft: the highest peak migration was after 2 years. You
reported the results after 1 year. Do you have any other data after
this interval?
And the second question is this: since you couldn’t find any
correlation between migration and neck dilatation, can you spec-
ulate where this migration is coming from? What is the cause since,
you have no
Dr Sternbergh. I very much agree with you that migration is
a time-dependent phenomenon and 12 months is fairly early. I
don’t have any available data yet on more long-term migration, but
certainly that’s going to be an important thing to keep an eye on.
Your last question really is another question of why are these
migrating. And the bottom line is that we don’t know. We looked
very hard for other anatomic characteristics that perhaps were the
causative factor(s), and the 30% oversizing was simply a surro-
gate, but we could not find them.
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